Dr. A. Shtil received his MD degree in Orenburg State Medical Institute and PhD in Moscow Research Institute of Otorhinolaryngology. In 1994-2002 he worked in the University of Illinois at Chicago, Lee Moffitt Cancer Center and Sloan-Kettering Cancer Institute, studying the mechanisms of multidrug resistance and altered drug response in cancer (with I.Roninson, W.Dalton and K.Scotto). After returning home he established a new laboratory of tumor cell death at Blokhin Cancer Center with broad interests in cancer biology. The laboratory is studying the molecular mechanisms of cytocidal effects of small molecular weight compounds as perspective anticancer drug candidates. Our particular interest is novel DNA ligands, including the derivatives of anthraquinone and porphyrins that target the double helix and complex DNA structures. We also investigate the anti-apoptotic and pro-proliferation protein kinases of Pim family as a druggable target for newly developed indole based inhibitors. International cooperation includes the European Consortium “Protein kinases – Novel Drug Targets of Post Genomic Era” and contacts with groups in the United States, France, Japan and Taiwan. In 2018-2000 A.Shtil is a group leader in the Megagrant ‘CDK8-mediated transcriptional reprogramming: interface of biology and medicine’ with I. Roninson (USA) as a chief scientist. Since 2016 A. Shtil joined the ITMO University at Saint-Petersburg (SCAMT laboratory) where a group of young investigators is working on linking the materials science with molecular oncology. Dr. Shtil has authored more than 150 scientific papers, review articles and a number of patents. He is member of editorial boards in four international journals.